WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.
GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.
J.P. Morgan Chase increased its stake in Weichai Power (02338) by approximately 1.79 million shares, with a price of approximately 27.58 Hong Kong dollars per share.
CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.
GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.
J.P. Morgan Chase increased its stake in Weichai Power (02338) by approximately 1.79 million shares, with a price of approximately 27.58 Hong Kong dollars per share.
RECOMMEND
“Memory Price Surge” For 100 Days, Low‑End Smartphones Forced Into Decline
19/03/2026
Hong Kong Suddenly Becomes A New Destination For Middle Eastern Capital? Signs Of Increased Allocation Are Evident
19/03/2026
Memory Price Surge Persists For 100 Days, Forcing Low‑End Smartphones Toward Extinction
19/03/2026
